GC Biotherapeutics Inc.

GC Biotherapeutics Inc. (GCBT) is the strategic foothold for GC’s business expansion to the North American and European markets. We are building a state of the art bio-manufacturing facility for plasma proteins and will be the only Intravenous Immunoglobulin (IVIG) and Albumin producer in Canada.

More

Product list

GC Biotherapeutics Inc. (GCBT) will initially manufacture two products: Intravenous Immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and Albumin, used as a blood-volumizing agent.                                                                                     

More

Contact us

For all inquiries about GC Biotherapeutics Inc., Project Oasis, corporate information, customer relations or about any of our products, click “More” to send us a message.

More

Recent News

09Nov

GCAM Adds New Plasma Collection Centers

0 Comments
YONGIN, South Korea, Nov. 9, 2018 /CNW/ — GCAM, Inc., a U.S. based plasma collection company, announced that it has added two additional... Read More →
09Nov

Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate

0 Comments
SEATTLE and YONGIN, South Korea, Nov. 5, 2018 /CNW/ — Curevo, a Seattle-based biotechnology company owned by GC Pharma, one of the largest therapeutic protein... Read More →

A Major Project in Canada

Project Oasis

Project Oasis is a plan to expand GC’s business to North America and Europe. Its Montreal plant will be the project’s focal point. $400 million will be invested in Canada’s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.

More

GC Mogam Inc.

Located in Fort Lee, New Jersey, GC Mogam has been established by GCBT to perform Sales & Marketing functions across the United States. GC Mogam’s website will be coming soon. In the meantime, please click the logo below for more information.

 

 

Back to Top